Sk Biopharmaceuticals Co Stock Revenue
| 326030 Stock | 106,300 1,100 1.05% |
Sk Biopharmaceuticals Co fundamentals help investors to digest information that contributes to Sk Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of 326030 Stock. The fundamental analysis module provides a way to measure Sk Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sk Biopharmaceutica stock.
326030 |
Sk Biopharmaceuticals Co Company Revenue Analysis
Sk Biopharmaceutica's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Sk Biopharmaceutica Revenue | 418.64 B |
Most of Sk Biopharmaceutica's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sk Biopharmaceuticals Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Sk Biopharmaceuticals Co reported 418.64 B of revenue. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The revenue for all Republic of Korea stocks is significantly lower than that of the firm.
326030 Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sk Biopharmaceutica's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sk Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Sk Biopharmaceutica by comparing valuation metrics of similar companies.Sk Biopharmaceutica is currently under evaluation in revenue category among its peers.
326030 Fundamentals
| Return On Equity | -0.12 | |||
| Return On Asset | 0.0475 | |||
| Profit Margin | (0.12) % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 5.87 T | |||
| Shares Outstanding | 78.31 M | |||
| Shares Owned By Insiders | 64.28 % | |||
| Shares Owned By Institutions | 5.26 % | |||
| Price To Book | 15.89 X | |||
| Price To Sales | 13.94 X | |||
| Revenue | 418.64 B | |||
| Gross Profit | 396.31 B | |||
| EBITDA | 83.87 B | |||
| Net Income | 64.85 B | |||
| Cash Flow From Operations | (92.87 B) | |||
| Earnings Per Share | (117.74) X | |||
| Target Price | 96154.0 | |||
| Number Of Employees | 10 | |||
| Beta | 1.11 | |||
| Market Capitalization | 5.32 T | |||
| Total Asset | 643.65 B | |||
| Net Asset | 643.65 B |
About Sk Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sk Biopharmaceuticals Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sk Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sk Biopharmaceuticals Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Sk Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sk Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sk Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with 326030 Stock
Moving against 326030 Stock
The ability to find closely correlated positions to Sk Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sk Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sk Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sk Biopharmaceuticals Co to buy it.
The correlation of Sk Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sk Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sk Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sk Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in 326030 Stock
Sk Biopharmaceutica financial ratios help investors to determine whether 326030 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 326030 with respect to the benefits of owning Sk Biopharmaceutica security.